Trexquant Investment LP Invests $2.09 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Trexquant Investment LP acquired a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 94,923 shares of the company's stock, valued at approximately $2,092,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Clal Insurance Enterprises Holdings Ltd lifted its stake in Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after acquiring an additional 4,418,961 shares during the period. Lingotto Investment Management LLP boosted its stake in shares of Teva Pharmaceutical Industries by 2.6% during the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock valued at $599,320,000 after purchasing an additional 688,862 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Teva Pharmaceutical Industries by 2.2% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock valued at $573,822,000 after buying an additional 569,412 shares during the period. State Street Corp lifted its holdings in Teva Pharmaceutical Industries by 10.0% in the third quarter. State Street Corp now owns 19,500,683 shares of the company's stock worth $351,402,000 after buying an additional 1,778,268 shares during the period. Finally, Geode Capital Management LLC boosted its position in Teva Pharmaceutical Industries by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock valued at $203,642,000 after acquiring an additional 489,041 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Remove Ads

Teva Pharmaceutical Industries Stock Down 1.1 %

TEVA stock traded down $0.15 during midday trading on Monday, hitting $13.31. The company's stock had a trading volume of 777,195 shares, compared to its average volume of 9,883,085. The firm's 50-day moving average is $15.79 and its 200-day moving average is $17.82. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a market cap of $15.10 billion, a PE ratio of -9.18, a P/E/G ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TEVA. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Friday, April 4th. Bank of America decreased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Barclays dropped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Finally, UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.